

Drug resistance interpretation: PR

HIVDB 9.5.1 (2023-11-05)

PI Major Mutations:

None

PI Accessory Mutations:

None

PR Other Mutations:

L10I 99%
seen:0,405 • I13V 100%
seen:0,775 • E35D 100%
seen:0,280 • M36I 100%
seen:0,280 • R41K 97%
seen:0,303 • **K53H** 99%
seen:0,617 • R57K 100%
seen:0,241 • L63P 100%
seen:0,760 • H69K 97%
seen:0,279 • K70R 97%
seen:0,279 • V77I 100%
seen:1,801 • L89M 100%
seen:0,766

Protease Inhibitors

atazanavir/r (ATV/r)

Susceptible

darunavir/r (DRV/r)

Susceptible

fosamprenavir/r (FPV/r)

Susceptible

indinavir/r (IDV/r)

Susceptible

lopinavir/r (LPV/r)

Susceptible

nelfinavir (NFV)

Susceptible

saquinavir/r (SQV/r)

Susceptible

tipranavir/r (TPV/r)

Susceptible

PR comments

Other

L10I/V

are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.

Mutation scoring: PR	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT	HIVDB 9.5.1 (2023-11-05)
------------------------------------	--------------------------

NRTI Mutations:	None	
NNRTI Mutations:	None	
RT Other Mutations:	K11T 100% <small>seen:0,302</small> • K20R 100% <small>seen:0,307</small> • V21I 100% <small>seen:0,307</small> • V35M 100% <small>seen:0,308</small> • T39TAE 0-10% <small>seen:0,390</small> (A-100%, A-100%, T-100%) • V60I 100% <small>seen:0,117</small> • D121H 100% <small>seen:0,302</small> • K122E 100% <small>seen:0,385</small> • K173S 100% <small>seen:0,281</small> • Q174K 100% <small>seen:0,281</small> • I178IM 0-10% <small>seen:0,111</small> (M-10%, M-10%) • V179I 100% <small>seen:0,303</small> • T200A 100% <small>seen:1,114</small> • I202V 100% <small>seen:1,100</small> • Q207A 100% <small>seen:0,301</small> • R211S 100% <small>seen:0,29</small> • L517I 100% <small>seen:0,304</small> • Q524K 100% <small>seen:0,301</small> • K527E 100% <small>seen:0,300</small> • E529D 100% <small>seen:0,301</small> • K530Q 100% <small>seen:0,301</small> • A534S 100% <small>seen:0,301</small> • A554S 100% <small>seen:0,301</small> • K558R 100% <small>seen:0,301</small>	
Nucleoside Reverse Transcriptase Inhibitors		
abacavir (ABC)	Susceptible	
zidovudine (AZT)	Susceptible	
stavudine (D4T)	Susceptible	
didanosine (DDI)	Susceptible	
emtricitabine (FTC)	Susceptible	
lamivudine (3TC)	Susceptible	
tenofovir (TDF)	Susceptible	
Non-nucleoside Reverse Transcriptase Inhibitors		
doravirine (DOR)	Susceptible	
efavirenz (EFV)	Susceptible	
etravirine (ETR)	Susceptible	
nevirapine (NVP)	Susceptible	
rilpivirine (RPV)	Susceptible	

RT comments	
Other	
• V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.	

Mutation scoring: RT	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.

Drug resistance interpretation: IN	HIVDB 9.5.1 (2023-11-05)
------------------------------------	--------------------------

INSTI Major Mutations:	None
INSTI Accessory Mutations:	None
IN Other Mutations:	K14R 100% <small>seen:0,27</small> • V31I 99% <small>seen:0,302</small> • L43LQ 0-10% <small>seen:0,76</small> (L-10%, Q-10%) • V77VA 0-10% <small>seen:0,301</small> (V-10%, A-10%) • E96EG 0-10% <small>seen:0,301</small> (G-10%, G-10%) • L101I 100% <small>seen:0,401</small> • T112I 100% <small>seen:0,302</small> • T124G 100% <small>seen:0,301</small> • T125A 99% <small>seen:0,301</small> • K136Q 99% <small>seen:0,301</small> • D167DE 0-10% <small>seen:0,301</small> (D-10%, D-10%) • V201I 100% <small>seen:0,301</small> • T218I 100% <small>seen:0,301</small> • L234I 99% <small>seen:0,301</small> • S255SN 0-10% <small>seen:0,301</small> (S-10%, N-10%) • S283G 100% <small>seen:0,401</small>
Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

Mutation scoring: IN	HIVDB 9.5.1 (2023-11-05)
----------------------	--------------------------

No drug resistance mutations were found for INSTI.